Cibinqo (Abrocitinib) for Eczema

Overview
Cibinqo is approved by the U.S. Food and Drug Administration (FDA) for treating adults and adolescents aged 12 and older with moderate to severe atopic dermatitis (the most common type of eczema) that is not well-managed by other systemic treatments, such as biologics, or when those therapies are not suitable. Cibinqo is also known by its drug name, abrocitinib.

Cibinqo belongs to the Janus kinase (JAK) inhibitor category of medications. It is believed to work by blocking certain enzymes involved in the inflammatory processes associated with eczema, thereby reducing symptoms like itching, discoloration, and swelling.

How do I take it?
Prescribing information states that Cibinqo is taken orally in tablet form, once daily. Dose size may be increased if the initial dose doesn’t provide symptom relief. It is important to take Cibinqo exactly as prescribed by a healthcare provider.

Side effects
Common side effects of Cibinqo include nasopharyngitis (cold-like symptoms), nausea, headache, herpes simplex (cold sores), increased blood creatine kinase (an enzyme that can indicate muscle damage), dizziness, urinary tract infection, fatigue, acne, vomiting, impetigo (a skin infection), oropharyngeal pain (throat pain), hypertension (high blood pressure), influenza (flu), gastroenteritis (stomach flu), and contact dermatitis (skin irritation).

Rare but serious side effects may include severe infections (such as tuberculosis), malignancies (cancers) like lymphomas and lung cancers, major adverse cardiovascular events including cardiovascular death, myocardial infarction (heart attack), and stroke, and thrombosis (blood clots), including pulmonary embolism and deep vein thrombosis.

For more information about this treatment, visit:

Label: Cibinqo — Abrocitinib Tablet, Film Coated — DailyMed

Cibinqo  — Drugs.com